CapsoVision (CV) FCF Margin (2024 - 2025)
CapsoVision (CV) reported FCF Margin of 196.17% for Q4 2025, down 4423.0% on a YoY basis from 4.54% in Q4 2024, and down 22.49% sequentially from 160.15% in Q3 2025.
CapsoVision (CV) FCF Margin (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of FCF Margin data on file, last reported at 196.17% in Q4 2025.
- For the quarter ending Q4 2025, FCF Margin fell 4423.0% year-over-year to 196.17%; the trailing twelve-month figure through Dec 2025 stood at 130.75% (changed N/A YoY), and the FY2025 full-year result was 168.69%, up 220.0% from the prior year.
- FCF Margin retreated to 196.17% in Q4 2025, from 160.15% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 151.94% in Q4 2024 to a low of 243.16% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 21.26% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -1.28% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 37.67% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.68% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | -196.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -196.17% |
| Sep 30, 2025 | -160.15% |
| Dec 31, 2024 | -151.94% |
| Sep 30, 2024 | -243.16% |